Institute of Haematology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2065, Australia.
Semin Thromb Hemost. 2012 Jun;38(4):375-84. doi: 10.1055/s-0032-1311991. Epub 2012 May 9.
The main laboratory characteristic of lupus anticoagulants (LA) is their ability to prolong phospholipid-dependent clotting time in vitro. The laboratory demonstration of LA requires a systematic approach combined with an awareness of the many variables that can affect test results. The ideal testing procedures are those sensitive enough to detect weak LA and specific enough so as not to produce incorrect conclusions. International guidelines have been published to assist laboratories in applying correct testing processes. The most recently published guidelines from the International Society on Thrombosis and Haemostasis update the criteria for detecting the presence of LA that were presented in the 1995 guidelines. Some of the specific recommendations relate to the key areas of setting cut-off levels for screening, mixing, and confirmatory procedures. The more challenging aspects of testing for LA include maintaining sensitivity and specificity of the assays, especially in the presence of anticoagulant therapy.
狼疮抗凝物(lupus anticoagulants,LA)的主要实验室特征是其在体外延长磷脂依赖性凝血时间的能力。LA 的实验室检测需要结合系统的方法和对许多可能影响检测结果的变量的认识。理想的检测程序应足够敏感以检测弱 LA,并且特异性足够高,以免得出错误的结论。已经发布了国际指南,以帮助实验室应用正确的检测流程。最近发布的国际血栓形成和止血学会指南更新了 1995 年指南中提出的检测 LA 存在的标准。一些具体建议涉及筛选、混合和确认程序的截止值设置的关键领域。检测 LA 更具挑战性的方面包括保持检测的敏感性和特异性,尤其是在抗凝治疗的情况下。